Workflow
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
femasysfemasys(US:FEMY) Globenewswire·2025-11-03 21:30

-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- 12millionseniorsecuredconvertiblenotesfortotalpotentialproceedsof12 million senior secured convertible notes for total potential proceeds of 58 million, if all warrants are exercised for cash, reflecting strong investor confidence in Femasys’ women’s health mission -- ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical ...